Gurubhagavatula et al (2004) showed that increasing numbers of either XPD or XRCC1 variant alleles and a greater number of variant alleles in combinations of both genes are associated with shorter overall survival after therapy with platinum agents for non-small-cell lung cancer. The gene discussed is XRCC1; the disease is non-small cell lung carcinoma.